CS-Keys

CS-Keys is a preclinical-stage biotechnology company dedicated to developing precision medicines for cancer by targeting unique protein isoforms. Spun out of Johns Hopkins University, the company utilizes a proprietary proteomics platform to identify 'keys'—specific protein variants that drive disease but are absent in healthy tissue. Their primary focus is on the polyamine metabolic pathway, specifically targeting spermine oxidase (SMOX) to treat various solid tumors. By focusing on these highly specific targets, CS-Keys aims to create therapies with high efficacy and minimal off-target toxicity. The company is currently advancing its lead programs through early-stage validation and lead optimization.